Thermo Fisher Scientific (NYSE:TMO) Now Covered by Analysts at Redburn Atlantic

Equities research analysts at Redburn Atlantic assumed coverage on shares of Thermo Fisher Scientific (NYSE:TMO) in a research report issued to clients and investors on Monday, Briefing.com reports. The firm set a “buy” rating on the medical research company’s stock.

A number of other research firms have also weighed in on TMO. Robert W. Baird increased their target price on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Evercore ISI lifted their price objective on shares of Thermo Fisher Scientific from $605.00 to $630.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. UBS Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Monday, September 16th. Stephens initiated coverage on Thermo Fisher Scientific in a report on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price target for the company. Finally, TD Cowen lifted their target price on Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Four analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $653.72.

Thermo Fisher Scientific Trading Down 0.0 %

TMO stock traded down $0.12 during mid-day trading on Monday, reaching $596.80. 65,160 shares of the stock traded hands, compared to its average volume of 1,463,059. The business has a 50-day moving average price of $607.73 and a two-hundred day moving average price of $583.46. The stock has a market capitalization of $227.98 billion, a PE ratio of 37.09, a PEG ratio of 3.80 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. Thermo Fisher Scientific has a one year low of $415.60 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. During the same quarter last year, the firm earned $5.15 earnings per share. The firm’s quarterly revenue was down 1.4% compared to the same quarter last year. Equities research analysts expect that Thermo Fisher Scientific will post 21.72 EPS for the current year.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 860 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $611.03, for a total value of $525,485.80. Following the completion of the sale, the chief accounting officer now owns 1,814 shares of the company’s stock, valued at $1,108,408.42. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $1,201,700.00. Following the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at $7,860,920.55. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Joseph R. Holmes sold 860 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $611.03, for a total value of $525,485.80. Following the sale, the chief accounting officer now directly owns 1,814 shares of the company’s stock, valued at approximately $1,108,408.42. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 23,084 shares of company stock valued at $14,094,292. Corporate insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $295,000. Congress Asset Management Co. MA lifted its position in Thermo Fisher Scientific by 20.0% during the fourth quarter. Congress Asset Management Co. MA now owns 20,095 shares of the medical research company’s stock valued at $10,666,000 after purchasing an additional 3,343 shares during the period. Nomura Holdings Inc. purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at $15,005,000. Park National Corp OH purchased a new stake in shares of Thermo Fisher Scientific in the first quarter worth about $207,000. Finally, Orrstown Financial Services Inc. acquired a new stake in Thermo Fisher Scientific during the first quarter worth about $280,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.